Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (68)	8/28/2006 8:35:20 PM
From: zeta1961	Read Replies (1) \| Respond to of 760

It would seem that studying malignant brain tumors might be an unlikely way to try to validate and improve cancer vaccines in general and a long shot for attempting to develop clinically effective cancer vaccination. There is, however, one parallel between malignant brain tumor growth and immunity that is intriguing. Malignant gliomas grow substantially faster in older patients who, incidentally, usually have defects in the kind of immune cells able to recognize and kill tumors. In addition, individuals with immune systems that are so hyperactive they attack certain portions of their own bodies (autoimmune patients) have a significantly reduced risk of acquiring a brain tumor, suggesting that hyperimmunity might prevent brain tumors. Thus, investigators within Cedars-Sinai's Maxine Dunitz Neurosurgical Institute's (MDNSI) Immunology Program sought to determine if malignant brain tumors were sensitive to immune activity and to identify the specific immune parameter that might contribute to age-dependent brain tumor progression csmc.edu